Lupin Launches Generic ZYMAXID™ Ophthalmic Solution in the US
MUMBAI, India and BALTIMORE, October 3, 2013
MUMBAI, India and BALTIMORE, October 3, 2013 /PRNewswire/ --
Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary,
Lupin Pharmaceuticals, Inc. (LPI), has launched its generic Gatifloxacin
Ophthalmic Solution, 0.5%. Lupin had earlier received final approval from the
United States Food and Drugs Administration (US FDA) to market a generic
version of Allergan Inc.'s Zymaxid™ Ophthalmic Solution, 0.5%.
Lupin's Gatifloxacin Ophthalmic solution 0.5% is the generic equivalent of
Zymaxid™ Ophthalmic Solution of Allergan and is indicated for the treatment of
bacterial conjunctivitis. Zymaxid™ Ophthalmic Solution, 0.5%, had annual U.S
sales of approximately US$ 62.3 million (IMS MAT Jun 2013). Lupin was the
first applicant to file an ANDA for Zymaxid™ Ophthalmic Solution and as such
will be entitled to 180 days of marketing exclusivity.
Commenting on the approval, Nilesh Gupta, Managing Director, Lupin Limited,
said, "Having received approval earlier, we are happy to now launch this
product. The product is the first of the ophthalmic products that Lupin is
bringing to the market and bears testimony to our continued commitment to
serving our customers and patients by bringing high quality, affordable
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company producing and
developing a wide range of branded and generic formulations and APIs globally.
The Company is a significant player in the Cardiovascular, Diabetology,
Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global
leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 5th largest and fastest growing top 5 generics player in the US
(5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian
pharmaceutical company by sales. The Company is also the fastest growing top
10 generic pharmaceutical players in Japan and South Africa (IMS).
For the financial year ended March 2013, Lupin's Consolidated turnover and
Profit after Tax were Rs. 94,616 million (USD 1.74 billion) and Rs. 13,142
million (USD 242 million) respectively. Please visit http://www.lupinworld.com
for more information.
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated
to delivering high-quality, affordable generic medicines and branded
formulations trusted by healthcare professionals and patients across
geographies. For more information, visit http://www.lupinpharmaceuticals.com
Safe Harbor Statement
* Zymaxid™ is the registered trademark of Allergan Inc.
For more information, please contact -
Head - Corporate Communications
SOURCE Lupin Ltd
Press spacebar to pause and continue. Press esc to stop.